

**IBC Meeting Minutes
October 7th, 2025**

Topic	Notes
Institution	Michigan Technological University
Meeting Date	October 7th, 2025
Meeting Time	Meeting Started at 4pm
Meeting Type	Virtual (Zoom)
IBC Members Present	Jari Sague, David Dixon, Michael LaBeau, Ashutosh Tiwari, Victor Busov, Kaitlyn Studinger, Xiaoqing Tang
Quorum	5 to have quorum
Other Individuals in Attendance	Brent Burns, AVPRI
Call to Order	Call to Order at 4pm
Conflicts of Interest	No conflicts of interest
Review and approval of previous meeting minutes	Minutes were approved unanimously
Review of Prior Business	No prior business
New IBC Registrations and Amendments for Review (repeat for each registration)	
PI Name(s)	Zhengpeng Wan

Registration Number/Title	IBC-00000059 - Engineering vascularized tissues for disease modeling
Project Overview	<p>Development of advanced in vitro human tissue models using cancer cell lines (some are BSL-2)</p> <p>To achieve these goals, several primary human cells, established human cell lines, and human-induced pluripotent stem cells (hiPSCs) will be utilized.</p> <p>To facilitate these studies, a lentivirus system will be used to generate stable cell lines expressing fluorescent markers (GFP, BFP, mCherry, etc.) and for the delivery of CRISPR-Cas9 guide RNAs to generate gene knockouts.</p>
NIH Guidelines Section	<p>III-D-1 - Use of Risk Group 2, 3, 4 or restricted agents as host-vector system. Examples include: Adenovirus, Herpes virus, Lentivirus, Amphotrophic or VSVg pseudotyped Murine Retrovirus, Human Retrovirus, Vaccinia virus, Vesicular Stomatitis virus, and Adeno Associated virus with helper virus.</p> <p>III-E-1 - Cell culture experiments where there is < 2/3 of any eukaryotic virus in the absence of helper viruses or helper plasmids. For such experiments, it must be demonstrated that the cells lack helper virus for the specific Families of defective viruses being used.</p>
Risk Assessment and Discussion	<p>The lab is operating at BSL-2, however all cell lines are listed through ATCC as BSL-1. The PI has stated that he will follow all related safety measures as listed in the University Biosafety Manual.</p> <p>Disclaimer related to BSL -2 related protocols: At Biosafety Level 2 (BSL2), the primary concerns include accidental needlesticks, cuts, and exposures of infectious materials to mucous membranes. Although the organisms typically handled at BSL2 are not known to be transmitted through aerosols, procedures that generate aerosols or have a high potential for splashing may increase the risk of exposure for personnel. In the event of accidental exposure, each case will be evaluated as it arises.</p>
Training	SafetySkills certificates for BSL-2 and Bloodborne Pathogen training are attached in the protocol.

Occupational Health Representative review (if applicable):	N/A
Biosafety Level Assignment	BSL-2
IBC Vote	The committee voted unanimously to have the subsequent review be a DMR after FCR
New Business/ Biosafety Program Report	Nothing to report.
Review of Incidents	No incidents have taken place since our last meeting
Inspections/ Ongoing Oversight	No IBC inspections have taken place since our last meeting
IBC Training	No formal training has taken place since our last meeting.
Approved Protocols	See table below
Public Comments	No public comments.
Adjournment	Meeting adjourned at 4:29pm

PI	Protocol	Version	Title	Approve Date	Review Date	Expiration Date	Type of Approval
Tang, Xiaohu	IBC-00000005	2	Targeting Metabolic Vulnerabilities in LKB1-Mutant Cancers via PDE3 Modulation Mechanisms	9/22/2025	9/22/2026	9/22/2028	De Novo - Approved by Admin and BSO after FCR